β³ Fetching live dividend data...
Home βΊ Calculator βΊ PRTA Dividend Calculator 2026
Prothena Corporation plc Β· NASDAQ
Price: $9.05 Β· Annual div: None Β· Frequency: β Β· Payout ratio: N/A Β· Ex-div: β
PRTA is not a dividend-focused stock
PRTA pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Prothena Corporation plc (PRTA) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual AΓ-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-AΓ antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
No. Prothena Corporation plc (PRTA) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. PRTA has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data Β· open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open PRTA position with:
Real after-tax yield depends on where you live and how you hold PRTA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| π©πͺ DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| π«π· FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
PRTA pays quarterly β 4 times per year. Ex-div: β.
How PRTA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PRTA sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2026-10-14 | 10,000 | $8.46 | $84.6K | ||
| Buy | 2026-10-13 | 100,000 | $8.35 | $835.5K | ||
| Buy | 2026-10-08 | 90,000 | $8.57 | $770.9K | ||
| Buy | 2026-10-07 | 125,000 | $8.40 | $1.05M | ||
| Buy | 2026-10-02 | 100,000 | $8.57 | $857.2K | ||
| Buy | 2026-09-29 | 162,000 | $8.68 | $1.41M | ||
| Buy | 2026-09-28 | 103,500 | $8.60 | $889.9K | ||
| Buy | 2026-09-18 | 100,000 | $8.43 | $843.5K | ||
| Buy | 2026-09-02 | 27,000 | $9.47 | $255.7K | ||
| Buy | 2026-08-20 | 50,000 | $8.79 | $439.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Compare PRTA with peers: PRTA vs BCYC Β· PRTA vs CRVS Β· PRTA vs FDMT
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Insiders are net buyers β historically a positive signal for dividend sustainability. Last purchase: 2026-10-14
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PRTA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Prothena Corporation plc (PRTA) is currently trading at $9.05, 23% below its 52-week high. It does not currently pay a regular dividend.
Prothena Corporation plc (PRTA) is a healthcare stock trading at $9.05. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only β not financial advice.
News aggregated from public sources via Finnhub & RSS. For informational purposes only.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever